SEC Comment Letter for AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Mar 24, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: March 24, 2016 · CIK: 0001385818 · Accession: 0000000000-16-069634
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210144
Letter
Mail Stop 4720 March 24 , 2016 Joshua R. Disbrow Chief Executive Officer Aytu Bioscience, Inc. 373 Inverness Parkway Suite 206 Englewood, Colorado 80112
Re: Aytu Bioscience, Inc. Registration Statement on Form S -1 Filed March 11 , 2016 File No. 333-210144
Dear Mr. Disbrow :
This is to advise you that we have not reviewed and will not review your registration statement .
We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.
In the event you request acceleration of the effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that:
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
the action of the Commission or the staff, acting pursuant t o delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
the company may not assert staff comments and the declaration of effect iveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Joshua R. Disbrow Aytu Bioscience, Inc. March 24 , 2016 Page 2
Please refer to Rules 460 and 461 regarding requests for acceleration . We will consider a written request for acceler ation of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities .
Please contact Alla Berenshteyn at (202) 551-4325 or me at (202) 551 -3675 with any questions.
Sincerely,
/s/ Suzanne Hayes
Show Raw Text
Mail Stop 4720 March 24 , 2016 Joshua R. Disbrow Chief Executive Officer Aytu Bioscience, Inc. 373 Inverness Parkway Suite 206 Englewood, Colorado 80112 Re: Aytu Bioscience, Inc. Registration Statement on Form S -1 Filed March 11 , 2016 File No. 333-210144 Dear Mr. Disbrow : This is to advise you that we have not reviewed and will not review your registration statement . We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 193 3 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In the event you request acceleration of the effective date of the pending regist ration statement , please provide a written statement from the company acknowledging that: should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; the action of the Commission or the staff, acting pursuant t o delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and the company may not assert staff comments and the declaration of effect iveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Joshua R. Disbrow Aytu Bioscience, Inc. March 24 , 2016 Page 2 Please refer to Rules 460 and 461 regarding requests for acceleration . We will consider a written request for acceler ation of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the registered securities . Please contact Alla Berenshteyn at (202) 551-4325 or me at (202) 551 -3675 with any questions. Sincerely, /s/ Suzanne Hayes Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Alexander M. Donaldson, Esq. Wyrick Roberts Yates & Ponton LLP